

MONOGRAPHS FOR DRUG-DRUG INTERACTIONS OF THERAPEUTICS BIOLOGICS

JOCELYN LEU, SIMONE KASEK, CHRISTINE LI, WARARAT LIMOTHAI, DORA BABU MADHURA, CHETAN RATHI, SUMIT RAWAL, JOSIAH RYMAN, MARGARET THOMSON, ASHIT TRIVEDI, HONGHUI ZHOU, and BERND MEIBOHM

Over the last decade, the unprecedented increase in the clinical use of therapeutic biologics for a variety of indications including immune-mediated inflammatory disease indications such as rheumatoid arthritis and inflammatory bowel diseases, and oncology indications has resulted in a new class of drug-drug interactions, therapeutic biologic-drug interactions. However, this kind of drug-drug interactions is generally understudied or underreported due to a perception that drug-drug interactions involving therapeutic biologics are scarce and of limited relevance. Moreover, the underlying mechanisms of many of those drug-drug interactions are still poorly understood.

In order to better assess the landscape of drug-drug interactions for therapeutic biologics, we have compiled drug-drug interaction monographs involving therapeutic biologics either as victims or perpetrators based on current US labeling information and scientific literature. To broaden our knowledgebase in this area, our monographs also include some important 'theoretical' drug-drug interactions with well established plausible mechanisms. In order to make those monographs more useful to the readers, we have also included other relevant references if available from which the drug-drug interaction contents was obtained. We feel these monographs might be useful for readers as they might guide expectations in what might be encountered as potential therapeutic biologic-drug interaction in clinical development programs and applied pharmacotherapy.